Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
NCT00673816
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
2
Enrollment
NIH
Sponsor class
Stopped
Inability to recruit and adequate number of participants
Conditions
Von Hippel-Lindau Syndrome
Interventions
DRUG:
Sunitinib Malate
Sponsor
National Eye Institute (NEI)